AEs With TROP2 ADCs

CME

Identification and Management of AEs With TROP-2–Targeted ADCs

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: April 04, 2024

Expiration: April 03, 2025

Matthew Gubens
Matthew Gubens, MD, MS, FASCO

Activity

Progress
1 2
Course Completed

References

  1. Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329-2340.
  2. Shastry M, Jacob S, Rugo HS, et al. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. Breast. 2022;66:169-177.
  3. Bardia A, Krop I, Meric-Bernstam F, et al. Datopotamab deruxtecan (Dato-DXd) in advanced triple-negative breast cancer (TNBC): updated results from the phase 1 TROPION-PanTumor01 study. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract P6-10-03.
  4. Yasuda S, Maejima T, Toki T, et al. Evaluation of bystander antitumor effect of Dato-DXd in TROP2 (+) and TROP2 (-) lung cell lines admixed tumor xenograft mouse models. Presented at: 2023 American Association for Cancer Research Annual Meeting; April 14-19, 2023. Abstract 4893.
  5. Sacituzumab govitecan [prescribing information]. Foster City, CA: Gilead Sciences; 2023.
  6. Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496-22512.
  7. Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019;11:987-995.
  8. Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel). 2023;15:713.
  9. Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017;35:2790-2797.
  10. Shimizu T, Sands J, Yoh K, et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41:4678-4687.
  11. D’Arienzo A, Verrazzo A, Pagliuca M, et al. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. EClinicalMedicine. 2023;62:102113.
  12. Henning JW, Brezden-Masley C, Gelmon K, et al. Managing the risk of lung toxicity with trastuzumab deruxtecan (T-DXd): a Canadian perspective. Curr Oncol. 2023;30:8019-8038.
  13. Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7:1873-1881.
  14. Spring LM, Nakajima E, Hutchinson J, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities. Oncologist. 2021;26:827-834.